Design Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Design Therapeutics, Inc. (DSGN) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-04-28
- Design Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Design Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $54.00K.
- Design Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was -$163.00K.
- Design Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was $203.00K.
- Design Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $25.00K.
- Design Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $29.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-04-28 | |||
| 2025-03-31 | $54.00K 10-Q · filed 2026-04-28 | |||
| 2023-12-31 | $25.00K 10-K · filed 2025-03-10 | |||
| 2022-09-30 | -$163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $40.00K derived: sum of 2 quarters · filed 2023-11-13 | $59.00K 10-Q · filed 2023-11-13 | -$24.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $203.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $222.00K 10-Q · filed 2023-08-14 | $139.00K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $19.00K 10-Q · filed 2023-05-09 | -$64.00K derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $29.00K 10-K · filed 2023-03-14 | ||
| 2021-09-30 | $112.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |